Kun Run Biotechnology Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net revenues were $4.0 million, up 65% from $2.4 million in the third quarter of 2008. This increase was mainly attributable to the increase in sales of products. Operating income was $2.4 million, or 59% of revenue, an increase of 114% from $1.1 million, or 46% of revenue, in the third quarter of 2008. Net income was $2.0 million, or $0.08 per basic and diluted share, compared to a net income of $0.865 million, or $0.04 per basic and diluted share, in the third quarter of 2008. The company reported income before income taxes and non controlling interest of $2.42 million compared to $1.04 million for the same period last year. For the nine months ended September 30, 2009, the company reported net revenue was $10.1 million, up 30% from $7.8 million in the period ended September 30, 2008. Operating income was $6.0 million, or 59% of revenue compared to $4.02 million for the same period last year. Net income was $5.1 million or $0.20 per basic and fully diluted share, up 48% from $3.4 million, or $0.14 per fully diluted share in the nine-month period of 2008. The company reported income before income taxes and non controlling interest of $6.05 million compared to $3.78 million for the same period last year.

Kun Run Biotechnology Inc. announced financial results for the year ended December 31, 2008. Revenues for the year ended December 31, 2008 were $11.6 million, an increase of $4.1 million, or 56% over revenues for the same period of 2007. Income from operations increased 262% to $4.8 million in 2008 from $1.7 million for the year ended December 31, 2007. The sharp increase in income from operations was in part due to strong marketing and sales efforts and efficient cost control systems. Net income increased 378% to approximately $6.0 million for the year ended December 31, 2008. This was an improvement of approximately $4.8 million, from approximately $1.2 million for the same period of 2007. Comprehensive income was $6.8 million compared to $1.4 million in 2007. This increase was in line with the revenue growth and margin improvement and reflects income from disposing property that contributed an additional $2.4 million. Earnings per share for the year ended December 31, 2008 were $0.24 per basic and diluted share, compared with $0.05 per basic and diluted share for the same period of 2007. The increase was contributed by increased profitability in 2008. Excluding the effect of a $1.3 million 'Unusual Charge-Make Good Provision', the actual net income of 2008 was $7.3 million ($0.30 per share), representing a 482% increase over 2007. Income before income taxes and minority interest was $6,941,806 against $1,203,667 a year ago. Net cash provided by operating activities was approximately $5.8 million for the twelve months ended December 31, 2008.

Kun Run Biotechnology Inc. announced its financial results for the third quarter ended September 30, 2008. Net revenue was $2.4 million for the quarter ended September 30, 2008, up 16% from $2.1 million in the third quarter of 2007. This increase was mainly attributable to the increase in sales of products. Net income was $865,524, or $0.04 per share (basic and diluted), compared to a net income of $576,369, or $0.02 per share (basic and diluted), in the third quarter of 2007. Operating income was $1.1 million, or 46% of revenue, an increase from $793,998, or 38% of revenue, in the third quarter of 2007 due to the factors stated above. Net revenue was $7.8 million in the quarter ended September 30, 2008, up 57% from $5.0 million in the quarter ended September 30, 2007. Operating income was $1.5 million, or 20% of revenue. Net income was $3.4 million or $0.14 per basic and fully diluted share, up 250% from $0.86 million, or $0.04 per fully diluted share in the nine month period of 2007.